Gary Lyman, MD, MPH, senior lead for quality and policy at the Hutchinson Institute for Cancer Outcomes Research, explains that it may take 8-12 years to prove that biosimilars should be trusted in everyday clinical practice, as well as delves into issues of granting extrapolation.